Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2011-04-19
2011-04-19
Landsman, Robert (Department: 1646)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S011700, C514S021300, C530S300000
Reexamination Certificate
active
07928058
ABSTRACT:
Modified oxyntomodulin derivatives. Such derivatives can be used for the treatment of metabolic diseases such as diabetes and obesity.
REFERENCES:
patent: 6271011 (2001-08-01), Lee et al.
patent: 6692923 (2004-02-01), Lal et al.
patent: 7666835 (2010-02-01), Bloom et al.
patent: WO 01/83527 (2001-11-01), None
patent: WO 2004/062685 (2004-07-01), None
patent: WO 2006/134340 (2006-12-01), None
patent: WO 2007/056362 (2007-05-01), None
Dakin et al., End.145: 2687-2695, 2004.
Hinke et al., J. Biol. Chem., vol. 275 (2000), pp. 3827-3834, “Dipeptidyl peptidase IV (DPIV/CD26) degradation of glucagon”.
Bianchi Elisabetta
Eiermann George J.
Ingallinella Paolo
Marsh Donald J.
Mu Yingjun
Chandra Gyan
Istituto di Ricerche di Biologia Molecolare P. Angeletti S.p.A.
Landsman Robert
Merck Sharp & Dohme Corp.
Reilly John David
LandOfFree
Pharmaceutical composition comprising oxyntomodulin... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical composition comprising oxyntomodulin..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical composition comprising oxyntomodulin... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2734228